{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Belantamab&page=2", "query": { "intervention": "Belantamab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Belantamab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T15:15:31.698Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05461209", "title": "A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/ Refractory Multiple Myeloma" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" }, { "name": "Belantamab Mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-10-20", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05461209" }, { "nct_id": "NCT07224672", "title": "A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloidosis" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-06-24", "completion_date": "2033-01-12", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224672" }, { "nct_id": "NCT02343042", "title": "Selinexor and Backbone Treatments of Multiple Myeloma Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Belantamab Mafodotin", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2015-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343042" }, { "nct_id": "NCT04484623", "title": "Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2020-10-01", "completion_date": "2029-06-25", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 5, "location_summary": "Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04484623" }, { "nct_id": "NCT07217184", "title": "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-07-29", "completion_date": "2027-03-11", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217184" }, { "nct_id": "NCT03848845", "title": "Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "belantamab mafodotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2019-03-14", "completion_date": "2023-06-14", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03848845" }, { "nct_id": "NCT04676360", "title": "Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Plasmablastic Lymphoma", "Refractory Plasmablastic Lymphoma", "Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma" ], "interventions": [ { "name": "Belantamab Mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacob Soumerai, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-07-01", "completion_date": "2024-11-26", "has_results": true, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04676360" }, { "nct_id": "NCT05065047", "title": "Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-01-05", "completion_date": "2025-11-06", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05065047" }, { "nct_id": "NCT03544281", "title": "To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2018-09-20", "completion_date": "2024-02-28", "has_results": true, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Atlanta, Georgia + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03544281" }, { "nct_id": "NCT05556798", "title": "A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab Mafodotin", "type": "DRUG" }, { "name": "Nirogacestat", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2022-10-04", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-23T15:15:31.698Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05556798" } ] }